Pharmacyclics LLC
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1991-01-01
- Employees
- 607
- Market Cap
- -
- Website
- http://www.pharmacyclics.com
A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas
- Conditions
- Diffuse Large B-Cell LymphomaFollicular Lymphoma
- Interventions
- First Posted Date
- 2015-03-27
- Last Posted Date
- 2019-06-27
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 61
- Registration Number
- NCT02401048
- Locations
- 🇺🇸
Site-0343, Hackensack, New Jersey, United States
🇺🇸Site-0397, Birmingham, Alabama, United States
🇺🇸Site-0047, Duarte, California, United States
Study of Ibrutinib in Subjects With Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2015-01-30
- Last Posted Date
- 2018-08-14
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 36
- Registration Number
- NCT02351037
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸UC Davis Medical Center, Sacramento, California, United States
🇺🇸The University of Chicago Medical Center, Chicago, Illinois, United States
A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
- Conditions
- Chronic Lymphocytic LeukemiaSmall-Cell Lymphoma
- Interventions
- First Posted Date
- 2014-10-15
- Last Posted Date
- 2020-09-21
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 229
- Registration Number
- NCT02264574
- Locations
- 🇬🇧
Site Reference ID/Investigator# 0867, Harlow, Essex, United Kingdom
🇦🇺Site Reference ID/Investigator# 0888, Ballarat, Victoria, Australia
🇦🇹Site Reference ID/Investigator# 0869, Salzburg, Austria
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease
- First Posted Date
- 2014-07-21
- Last Posted Date
- 2019-07-11
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 45
- Registration Number
- NCT02195869
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia
- Conditions
- Waldenström's Macroglobulinemia
- Interventions
- First Posted Date
- 2014-06-17
- Last Posted Date
- 2021-03-03
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 181
- Registration Number
- NCT02165397
- Locations
- 🇺🇸
University of California Los Angeles, Los Angeles, California, United States
🇨🇦Princess Margaret Hospital, Toronto, Ontario, Canada
🇺🇸Stanford Cancer Center, Palo Alto, California, United States
Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Conditions
- Diffuse Large B Cell Lymphoma RelapsedDiffuse Large B Cell Lymphoma Refractory
- Interventions
- First Posted Date
- 2014-05-20
- Last Posted Date
- 2019-02-05
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 35
- Registration Number
- NCT02142049
- Locations
- 🇺🇸
SITE-1, Duarte, California, United States
🇺🇸SITE-10, Orange, California, United States
🇺🇸SITE-6, Bethesda, Maryland, United States
Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Conditions
- Refractory Diffuse Large B-Cell LymphomaRelapsed Diffuse Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2014-03-04
- Last Posted Date
- 2022-02-04
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 138
- Registration Number
- NCT02077166
- Locations
- 🇺🇸
Baylor Charles Sammons Cancer Center, Dallas, Texas, United States
🇺🇸Levine Cancer Institute, Charlotte, North Carolina, United States
🇺🇸Weill Cornell Medical Center, New York, New York, United States
Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma
- Conditions
- Follicular LymphomaB-cell LymphomaNon-Hodgkin's Lymphoma
- Interventions
- First Posted Date
- 2013-11-11
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 80
- Registration Number
- NCT01980654
- Locations
- 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸Comprehensive Cancer Centers of Nevada, Henderson, Nevada, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma
- First Posted Date
- 2013-11-11
- Last Posted Date
- 2019-10-16
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 63
- Registration Number
- NCT01980628
- Locations
- 🇬🇧
Site Reference ID/Investigator# 030, Manchester, England, United Kingdom
🇧🇪Site Reference ID/Investigator# 560, Ghent, Oost-vlaanderen, Belgium
🇬🇧Site Reference ID/Investigator# 814, Oxford, England, United Kingdom
Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2013-10-14
- Last Posted Date
- 2021-12-21
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 84
- Registration Number
- NCT01962792
- Locations
- 🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸University of California Los Angeles, Los Angeles, California, United States